Spiral talks with Ly-Mee Yu, Lead Statistician of the PANORAMIC Trial on the devastating effects of the pandemic and how trials like PANORAMIC, with the help of Spiral’s software, are aiming to provide better health outcomes for those affected by the virus.

REMAP-CAP, the Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia, has recently hit a significant date in its trial history, celebrating two years since the first Covid-19 ICU patient was randomised into the trial.

Spiral is pleased to announce our involvement in another incredibly exciting trial, aimed at producing effective Covid-19 treatments for critical care patients.

REMAP-CAP an application in Spiral’s study manifest, has recently been used in a collaborative clinical trial that focused on identifying effective treatments for critically ill Covid-19 patients.